Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 11Ifosfamide 9Radiotherapy 6tazemetostat 4pegfilgrastim 3cixutumumab 3Imatinib Mesylate 3Filgrastim 3Cyclophosphamide 3pazopanib 2Trabectedin 2Sunitinib 2Sorafenib 2Etoposide 2Dacarbazine 2Chemotherapy, Adjuvant 2trofosfamide 1tremelimumab 1temsirolimus 1soblidotin 1sargramostim 1romidepsin 1ribociclib 1reolysin 1poly ICLC 1perifosine 1pembrolizumab 1lorvotuzumab mertansine 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma, Synovial × soblidotin × Clear all
NCT00064220 2012-05-16

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Daiichi Sankyo

Phase 2 Completed
Sarcoma

Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡